Developer docs
API playgroundTry for free, no card

Search company profiles

AimedBio

Full company profile

uuid00028en

Namestring
AimedBio
Legal namestring
주식회사 에임드바이오
Websiteurl
aimedbio.com
Company typeenum
Public
Founded yearint
2018
Descriptiontext

AimedBio Inc. (주식회사 에임드바이오) is a Seoul-based clinical-stage biopharmaceutical company founded in August 2018 as a spin-off from Samsung Medical Center, specializing in antibody-drug conjugate (ADC) therapeutics for cancer. The company builds on its origin at Samsung Medical Center to operate a proprietary P-ADC™ (Precision-driven ADC) platform that integrates patient-derived cell (PDC) and patient-derived xenograft (PDX) validation into every stage of ADC development — from unmet-needs-based target discovery and antibody engineering through linker-payload optimization, translational research, and candidate selection. Its internal pipeline centers on two lead assets: AMB302, a first-in-class FGFR3-targeted ADC for bladder, head/neck cancer, and glioblastoma (exclusively licensed to Biohaven as BHV-1530 with FDA IND, MFDS IND, and FDA Orphan Drug Designation), and AMB303, a best-in-class ROR1 ADC for solid tumors using a co-developed Topo I inhibitor payload (AMB402) with Samsung Biologics. AimedBio also develops proprietary payloads (AMB401 duocarmycin, AMB402 camptothecin), an AVATASCAN® precision-medicine screening service, and a BsADC bispecific platform (PP1/PP2/PP3).

The company's business model is asset-centric B2B licensing rather than direct commercialization. AimedBio develops differentiated ADC candidates internally and out-licenses global rights to large pharmaceutical partners, generating revenue from upfront payments, development and regulatory milestones, sales milestones, and royalties. Confirmed licensing agreements include Biohaven for AMB302 (January 2025), Boehringer Ingelheim for a KRAS-mutant solid-tumor ADC valued up to $991 million (October 2025), and a co-development and option-to-license arrangement with SK Plasma for AMB303 (June 2025, option exercised December 2025). Additional revenue derives from co-development partnerships (Samsung Biologics, GeneQuantum, GC Cell, Sovargen) and Korean government grants via the Korea Drug Development Fund (KDDF).

Following a ₩40 billion Series B (July 2024), a ₩51.1 billion pre-IPO round (June 2025), and a ₩70.73 billion KOSDAQ IPO in December 2025 — the largest biotech listing on the exchange that year — AimedBio operates from headquarters in Songpa-gu, Seoul, with a wholly owned Singapore subsidiary (AVATAMED PTE Ltd.) supporting AVATASCAN® international commercialization. FY2025 consolidated revenue reached ₩47.3 billion (up from ₩11.76 billion in FY2024), with operating income of ₩20.8 billion versus a ₩408 million loss the prior year. The company is publicly traded on KOSDAQ under ticker 0009K0, with 64.67 million shares outstanding and a strategic shareholder base anchored by Samsung Life Science Fund, Yuhan Corporation, Intervest, and DS Asset Management.

Short descriptiontext

AimedBio is a Seoul-based clinical-stage biopharmaceutical company, spun off from Samsung Medical Center in 2018, that develops proprietary antibody-drug conjugates (ADCs) for cancer and out-licenses them to global pharmaceutical partners including Biohaven, Boehringer Ingelheim, and SK Plasma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody-drug conjugates, cancer therapeutics development, precision medicine screening, ADC licensing platform, oncology drug discovery
Industry3 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Oncology Drug Development
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Licensing & Transfer
TypeLicensing Royalties
Description

The company generates revenue through licensing out ADC assets to global pharmaceutical companies. This includes upfront payments, development milestones, regulatory milestones, and royalties on future sales. Key deals include Biohaven (AMB302) and Boehringer Ingelheim (ADC asset).

aimedbio.com
2Co-development Revenue
TypeProfessional Services
Description

Revenue from co-development partnerships where AimedBio contributes research/development capabilities in exchange for development funding, milestone payments, and shared commercialization rights. Partners include SK Plasma (AMB303), GeneQuantum, and Samsung Biologics.

aimedbio.com
3Government Grants
TypeProfessional Services
Description

Funding from Korea Drug Development Fund (KDDF) and other government programs supporting ADC development and brain disease treatments.

aimedbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1P-ADC™
Description

Proprietary precision-driven ADC development platform utilizing patient-derived models for target discovery, antibody engineering, and ADC optimization

aimedbio.com
+4 more records
Core offering1 text field

AimedBio develops antibody-drug conjugate (ADC) therapeutics for solid tumors using its proprietary P-ADC™ platform, which leverages patient-derived cell and xenograft models for target discovery, antibody engineering, ADC optimization, and translational research. The company generates revenue by licensing ADC candidates (AMB302, ODS025) and entering co-development agreements (AMB303) with global pharmaceutical companies such as Biohaven, Boehringer Ingelheim, and SK Plasma, while also providing AVATASCAN® precision medicine screening services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 107% survival extension in preclinical monotherapy studies for AMB302
+3 more records
Product overview1 text field

AimedBio is a biopharmaceutical company operating as a spin-off from Samsung Medical Center, developing a portfolio of antibody-drug conjugate (ADC) therapies through its proprietary P-ADC™ platform. The platform enables end-to-end ADC development from patient-derived target identification through clinical validation, supporting multiple pipeline candidates including AMB302 (FGFR3 ADC, licensed to Biohaven), AMB303 (ROR1 ADC), and ODS025 (licensed to Boehringer Ingelheim). The company also offers AVATASCAN® precision medicine screening services and develops proprietary payload technologies (AMB401 duocarmycin, AMB402 camptothecin).

Product and service5 records
1P-ADC™ Platform
CategoryBiopharmaceutical R&D Platform
Description

End-to-end ADC development platform using patient-derived models for target discovery, antibody engineering, ADC optimization, and translational research. Available for licensing and co-development engagements with pharmaceutical partners.

2AVATASCAN® Precision Medicine Screening Service
CategoryPrecision Medicine Services
Description

Precision medicine screening technology providing medical research services for cancer and disease research, using patient-derived avatars to identify root causes and develop new therapeutic possibilities for pharmaceutical and biotech customers.

3AMB302 (BHV-1530) - FGFR3 ADC
CategoryADC Pipeline Candidate
Description

First-in-class FGFR3-targeted antibody-drug conjugate for solid tumors including bladder cancer, head and neck cancer, and glioblastoma, with wide therapeutic index. Licensed exclusively to Biohaven for global development and commercialization as BHV-1530.

4AMB303 - ROR1 ADC
CategoryADC Pipeline Candidate
Description

Best-in-class ROR1-targeted ADC for solid tumors where ROR1 is overexpressed, including lung, breast, and ovarian cancer. Uses self-developed anti-ROR1 antibody with co-developed Topo I inhibitor payload (AMB402) from Samsung Biologics collaboration. Co-developed with SK Plasma.

5ODS025 - Anti-KRAS Solid Tumor ADC
CategoryADC Pipeline Candidate
Description

ADC candidate for solid tumors targeting KRAS mutations in lung, colorectal, and breast cancer. Licensed to Boehringer Ingelheim for global development and commercialization in a deal valued up to $991 million including upfront, development/regulatory/commercial milestones, and royalties.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-05-28
Description

Investment and joint research agreement to develop blood-brain barrier-crossing protein delivery platform. Combines Galux's AI protein design platform (GaluxDesign) with AimedBio's ADC development capabilities to enable antibody/protein therapeutics to reach brain tissue.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-03-31
Description

Joint development of Antibody-Oligonucleotide Conjugates (AOC) expanding from ADC to gene regulation therapeutics. Combines AimedBio's patient-derived cell-based antibody/target discovery with Sovargen's oligonucleotide design and manufacturing. Targeting oncology, metabolic, immune, and rare diseases.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2026-02-03
Description

Joint research agreement using AIVIS's AI-based digital pathology solution 'Qanti Discovery' to quantify pathology data and enhance biomarker-focused patient selection strategies. Includes strategic equity investment. Aims to improve clinical success probability through AI-based companion diagnostics.

4Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-15
Description

Global licensing agreement for ADC asset targeting KRAS mutations in various solid tumors. Total deal value up to $991 million including upfront, development/regulatory/commercial milestones, and royalties. Candidate uses Topo1 inhibitor payload with aim to enter Phase 1 in 2026.

aimedbio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-09
Description

Co-development and license option agreement for AMB303 (ROR1 ADC). SK Plasma exercises option for global co-commercialization rights. AimedBio handles basic research and candidate discovery; SK Plasma leads clinical and commercialization development. Option exercise fee received December 2025.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-14
Description

Exclusively licensed global development and commercialization rights for AMB302 (FGFR3 ADC, now BHV-1530) to Biohaven. AimedBio had planned to conduct clinical trials independently but partnered to leverage Biohaven's global clinical capabilities, enhancing probability of success. Deal terms confidential.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-13
Description

Equity investment through Samsung Life Science Fund plus R&D agreements to develop ADC technologies and monoclonal antibody therapies. Jointly developed Topo I inhibitor payload (AMB402). Plans for ADC manufacturing facility by 2024.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-04-19
Description

Co-development of AMB302 combining AimedBio's antibody with GeneQuantum's linker-payload and conjugation technology. Extended in June 2023 to potentially develop up to 5 additional ADCs. Enables brain tumor targeting ADC development.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-07-29
Description

CAR-NK cell therapy co-development using AimedBio's cancer-specific protein-binding antibody (AMB015) for CAR-NK therapy candidates. Expands beyond ADC into cell therapy domain.

10AVATAMED PTE Ltd (Singapore)
Strategic tierMinorTypeOthersAnnounced on2019-08-01
Description

Subsidiary established in Singapore for commercialization of precision medicine screening technology (AVATASCAN) in international markets.

aimedbio.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage ADC and immuno-oncology biotech developing novel ADC candidates. Comparable business model of developing ADC pipeline assets and pursuing partnership/licensing opportunities with larger pharmaceutical companies.

TypeEmerging player
Description

ADC platform company developing immune-stimulating antibody conjugates with proprietary linker technology. Similar technology-platform approach and clinical stage to AimedBio's preclinical-to-Phase 1 pipeline.

TypeDirect peer
Description

Emerging ADC platform company developing differentiated conjugation chemistries and payload technologies for ADCs. Comparable technology-platform approach to AimedBio's P-ADC™, both targeting out-licensing to global pharma.

TypeRegional player
Description

Korean ADC platform company developing proprietary linker technology and ADC candidates. Direct regional comparable also pursuing licensing deals with global pharma, with overlapping investor base and Korean biotech ecosystem positioning.

TypeDirect peer
Description

Clinical-stage ADC company developing next-generation antibody conjugates with proprietary linker-payload technology. Acquired by Genmab in 2024, illustrating the strategic value placed on differentiated ADC platforms similar to AimedBio's positioning.

TypeBroad incumbent
Description

Chinese biopharma with growing ADC pipeline and multiple licensing deals with global pharma including Eli Lilly. Comparable Asian-region origin and strategy of building ADC portfolio for global out-licensing, though larger scale and broader therapeutic focus.

TypeDirect peer
Description

Chinese ADC technology company specializing in site-specific conjugation and linker-payload technology. Already partnered with AimedBio on AMB302 development, demonstrating peer-level technology capabilities and shared customer base in global pharma.

TypeDirect peer
Description

Clinical-stage ADC-focused biotech developing first-in-class and best-in-class ADC candidates across multiple tumor targets. Directly comparable to AimedBio as a similarly sized pure-play ADC developer pursuing licensing deals with major pharma.

TypeEmerging player
Description

Clinical-stage biopharma that licensed AMB302 (now BHV-1530) from AimedBio and is developing FGFR3 ADC in-house. Comparable size and stage, with similar strategy of in-licensing differentiated ADC assets for clinical development.

TypeBroad incumbent
Description

Global ADC leader with Enhertu and Datroway, partnered with AstraZeneca. While a customer/partner candidate rather than competitor, Daiichi sets the licensing benchmark that AimedBio's platform output is benchmarked against.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AimedBio

Biopharmaceutical Oncology Drug Developmentaimedbio.com

AimedBio is a Seoul-based clinical-stage biopharmaceutical company, spun off from Samsung Medical Center in 2018, that develops proprietary antibody-drug conjugates (ADCs) for cancer and out-licenses them to global pharmaceutical partners including Biohaven, Boehringer Ingelheim, and SK Plasma.

What AimedBio does

AimedBio Inc. (주식회사 에임드바이오) is a Seoul-based clinical-stage biopharmaceutical company founded in August 2018 as a spin-off from Samsung Medical Center, specializing in antibody-drug conjugate (ADC) therapeutics for cancer. The company builds on its origin at Samsung Medical Center to operate a proprietary P-ADC™ (Precision-driven ADC) platform that integrates patient-derived cell (PDC) and patient-derived xenograft (PDX) validation into every stage of ADC development — from unmet-needs-based target discovery and antibody engineering through linker-payload optimization, translational research, and candidate selection. Its internal pipeline centers on two lead assets: AMB302, a first-in-class FGFR3-targeted ADC for bladder, head/neck cancer, and glioblastoma (exclusively licensed to Biohaven as BHV-1530 with FDA IND, MFDS IND, and FDA Orphan Drug Designation), and AMB303, a best-in-class ROR1 ADC for solid tumors using a co-developed Topo I inhibitor payload (AMB402) with Samsung Biologics. AimedBio also develops proprietary payloads (AMB401 duocarmycin, AMB402 camptothecin), an AVATASCAN® precision-medicine screening service, and a BsADC bispecific platform (PP1/PP2/PP3).

The company's business model is asset-centric B2B licensing rather than direct commercialization. AimedBio develops differentiated ADC candidates internally and out-licenses global rights to large pharmaceutical partners, generating revenue from upfront payments, development and regulatory milestones, sales milestones, and royalties. Confirmed licensing agreements include Biohaven for AMB302 (January 2025), Boehringer Ingelheim for a KRAS-mutant solid-tumor ADC valued up to $991 million (October 2025), and a co-development and option-to-license arrangement with SK Plasma for AMB303 (June 2025, option exercised December 2025). Additional revenue derives from co-development partnerships (Samsung Biologics, GeneQuantum, GC Cell, Sovargen) and Korean government grants via the Korea Drug Development Fund (KDDF).

Following a ₩40 billion Series B (July 2024), a ₩51.1 billion pre-IPO round (June 2025), and a ₩70.73 billion KOSDAQ IPO in December 2025 — the largest biotech listing on the exchange that year — AimedBio operates from headquarters in Songpa-gu, Seoul, with a wholly owned Singapore subsidiary (AVATAMED PTE Ltd.) supporting AVATASCAN® international commercialization. FY2025 consolidated revenue reached ₩47.3 billion (up from ₩11.76 billion in FY2024), with operating income of ₩20.8 billion versus a ₩408 million loss the prior year. The company is publicly traded on KOSDAQ under ticker 0009K0, with 64.67 million shares outstanding and a strategic shareholder base anchored by Samsung Life Science Fund, Yuhan Corporation, Intervest, and DS Asset Management.

AimedBio firmographics

Firmographics
Name
AimedBio
Legal name
주식회사 에임드바이오
Website
https://aimedbio.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
AimedBio is a Seoul-based clinical-stage biopharmaceutical company, spun off from Samsung Medical Center in 2018, that develops proprietary antibody-drug conjugates (ADCs) for cancer and out-licenses them to global pharmaceutical partners including Biohaven, Boehringer Ingelheim, and SK Plasma.
Ownership category
akta.pro rank

AimedBio industry classification

Industry
Product category
Biopharmaceutical Oncology Drug Development
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Antibody-drug conjugates
  • Cancer therapeutics development
  • Precision medicine screening
  • ADC licensing platform
  • Oncology drug discovery

Where AimedBio is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

AimedBio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Technology Licensing & Transfer: The company generates revenue through licensing out ADC assets to global pharmaceutical companies. This includes upfront payments, development milestones, regulatory milestones, and royalties on future sales. Key deals include Biohaven (AMB302) and Boehringer Ingelheim (ADC asset).
  2. Co-development Revenue: Revenue from co-development partnerships where AimedBio contributes research/development capabilities in exchange for development funding, milestone payments, and shared commercialization rights. Partners include SK Plasma (AMB303), GeneQuantum, and Samsung Biologics.
  3. Government Grants: Funding from Korea Drug Development Fund (KDDF) and other government programs supporting ADC development and brain disease treatments.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

AimedBio product offering

Product offering

Core offering

AimedBio develops antibody-drug conjugate (ADC) therapeutics for solid tumors using its proprietary P-ADC™ platform, which leverages patient-derived cell and xenograft models for target discovery, antibody engineering, ADC optimization, and translational research. The company generates revenue by licensing ADC candidates (AMB302, ODS025) and entering co-development agreements (AMB303) with global pharmaceutical companies such as Biohaven, Boehringer Ingelheim, and SK Plasma, while also providing AVATASCAN® precision medicine screening services.

Product overview

AimedBio is a biopharmaceutical company operating as a spin-off from Samsung Medical Center, developing a portfolio of antibody-drug conjugate (ADC) therapies through its proprietary P-ADC™ platform. The platform enables end-to-end ADC development from patient-derived target identification through clinical validation, supporting multiple pipeline candidates including AMB302 (FGFR3 ADC, licensed to Biohaven), AMB303 (ROR1 ADC), and ODS025 (licensed to Boehringer Ingelheim). The company also offers AVATASCAN® precision medicine screening services and develops proprietary payload technologies (AMB401 duocarmycin, AMB402 camptothecin).

Differentiator

Problem solved

Functional benefit

Brands

  • P-ADC™: Proprietary precision-driven ADC development platform utilizing patient-derived models for target discovery, antibody engineering, and ADC optimization
  • AVATASCAN®
  • AMB302
  • AMB303
  • ODS025

Products and services

  • P-ADC™ Platform End-to-end ADC development platform using patient-derived models for target discovery, antibody engineering, ADC optimization, and translational research. Available for licensing and co-development engagements with pharmaceutical partners.
  • AVATASCAN® Precision Medicine Screening Service Precision medicine screening technology providing medical research services for cancer and disease research, using patient-derived avatars to identify root causes and develop new therapeutic possibilities for pharmaceutical and biotech customers.
  • AMB302 (BHV-1530) - FGFR3 ADC First-in-class FGFR3-targeted antibody-drug conjugate for solid tumors including bladder cancer, head and neck cancer, and glioblastoma, with wide therapeutic index. Licensed exclusively to Biohaven for global development and commercialization as BHV-1530.
  • AMB303 - ROR1 ADC Best-in-class ROR1-targeted ADC for solid tumors where ROR1 is overexpressed, including lung, breast, and ovarian cancer. Uses self-developed anti-ROR1 antibody with co-developed Topo I inhibitor payload (AMB402) from Samsung Biologics collaboration. Co-developed with SK Plasma.
  • ODS025 - Anti-KRAS Solid Tumor ADC ADC candidate for solid tumors targeting KRAS mutations in lung, colorectal, and breast cancer. Licensed to Boehringer Ingelheim for global development and commercialization in a deal valued up to $991 million including upfront, development/regulatory/commercial milestones, and royalties.

Quantifiable outcome

  • 107% survival extension in preclinical monotherapy studies for AMB302
  • +3 more outcomes

Companies that use AimedBio

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

AimedBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

AimedBio partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered major, core and minor.

  • GaluxmajorStrategic or Co-development Partner · 28 May 2026Investment and joint research agreement to develop blood-brain barrier-crossing protein delivery platform. Combines Galux's AI protein design platform (GaluxDesign) with AimedBio's ADC development capabilities to enable antibody/protein therapeutics to reach brain tissue.
  • Sovargen (소바젠)majorStrategic or Co-development Partner · 31 March 2026Joint development of Antibody-Oligonucleotide Conjugates (AOC) expanding from ADC to gene regulation therapeutics. Combines AimedBio's patient-derived cell-based antibody/target discovery with Sovargen's oligonucleotide design and manufacturing. Targeting oncology, metabolic, immune, and rare diseases.
  • AIVIS (Avis)majorTechnology or Integration · 3 February 2026Joint research agreement using AIVIS's AI-based digital pathology solution 'Qanti Discovery' to quantify pathology data and enhance biomarker-focused patient selection strategies. Includes strategic equity investment. Aims to improve clinical success probability through AI-based companion diagnostics.
  • Boehringer IngelheimcoreStrategic or Co-development Partner · 15 October 2025Global licensing agreement for ADC asset targeting KRAS mutations in various solid tumors. Total deal value up to $991 million including upfront, development/regulatory/commercial milestones, and royalties. Candidate uses Topo1 inhibitor payload with aim to enter Phase 1 in 2026.
  • SK PlasmacoreStrategic or Co-development Partner · 9 June 2025Co-development and license option agreement for AMB303 (ROR1 ADC). SK Plasma exercises option for global co-commercialization rights. AimedBio handles basic research and candidate discovery; SK Plasma leads clinical and commercialization development. Option exercise fee received December 2025.
  • BiohavencoreStrategic or Co-development Partner · 14 January 2025Exclusively licensed global development and commercialization rights for AMB302 (FGFR3 ADC, now BHV-1530) to Biohaven. AimedBio had planned to conduct clinical trials independently but partnered to leverage Biohaven's global clinical capabilities, enhancing probability of success. Deal terms confidential.
  • Samsung BiologicscoreStrategic or Co-development Partner · 13 September 2023Equity investment through Samsung Life Science Fund plus R&D agreements to develop ADC technologies and monoclonal antibody therapies. Jointly developed Topo I inhibitor payload (AMB402). Plans for ADC manufacturing facility by 2024.
  • GeneQuantum (진퀀텀)majorStrategic or Co-development Partner · 19 April 2023Co-development of AMB302 combining AimedBio's antibody with GeneQuantum's linker-payload and conjugation technology. Extended in June 2023 to potentially develop up to 5 additional ADCs. Enables brain tumor targeting ADC development.
  • GC CellminorStrategic or Co-development Partner · 29 July 2022CAR-NK cell therapy co-development using AimedBio's cancer-specific protein-binding antibody (AMB015) for CAR-NK therapy candidates. Expands beyond ADC into cell therapy domain.
  • AVATAMED PTE Ltd (Singapore)minorOthers · 1 August 2019Subsidiary established in Singapore for commercialization of precision medicine screening technology (AVATASCAN) in international markets.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

AimedBio competitors and assessment

Company assessment

Direct peers

  • Pyxis Oncology: Clinical-stage ADC and immuno-oncology biotech developing novel ADC candidates. Comparable business model of developing ADC pipeline assets and pursuing partnership/licensing opportunities with larger pharmaceutical companies.
  • Tubulis: Emerging ADC platform company developing differentiated conjugation chemistries and payload technologies for ADCs. Comparable technology-platform approach to AimedBio's P-ADC™, both targeting out-licensing to global pharma.
  • ProfoundBio: Clinical-stage ADC company developing next-generation antibody conjugates with proprietary linker-payload technology. Acquired by Genmab in 2024, illustrating the strategic value placed on differentiated ADC platforms similar to AimedBio's positioning.
  • GeneQuantum Healthcare: Chinese ADC technology company specializing in site-specific conjugation and linker-payload technology. Already partnered with AimedBio on AMB302 development, demonstrating peer-level technology capabilities and shared customer base in global pharma.
  • Mersana Therapeutics: Clinical-stage ADC-focused biotech developing first-in-class and best-in-class ADC candidates across multiple tumor targets. Directly comparable to AimedBio as a similarly sized pure-play ADC developer pursuing licensing deals with major pharma.

Emerging players

  • Bolt Biotherapeutics: ADC platform company developing immune-stimulating antibody conjugates with proprietary linker technology. Similar technology-platform approach and clinical stage to AimedBio's preclinical-to-Phase 1 pipeline.
  • Biohaven: Clinical-stage biopharma that licensed AMB302 (now BHV-1530) from AimedBio and is developing FGFR3 ADC in-house. Comparable size and stage, with similar strategy of in-licensing differentiated ADC assets for clinical development.

Regional players

  • LegoChem Biosciences: Korean ADC platform company developing proprietary linker technology and ADC candidates. Direct regional comparable also pursuing licensing deals with global pharma, with overlapping investor base and Korean biotech ecosystem positioning.

Broad incumbents

  • Innovent Biologics: Chinese biopharma with growing ADC pipeline and multiple licensing deals with global pharma including Eli Lilly. Comparable Asian-region origin and strategy of building ADC portfolio for global out-licensing, though larger scale and broader therapeutic focus.
  • Daiichi Sankyo: Global ADC leader with Enhertu and Datroway, partnered with AstraZeneca. While a customer/partner candidate rather than competitor, Daiichi sets the licensing benchmark that AimedBio's platform output is benchmarked against.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

AimedBio social profiles

Digital presence

AimedBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AimedBio leadership team

Management profile

Number of profiles

Profiles13 records

AimedBio subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

AimedBio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AimedBio M&A and investment

M&A and investment

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AimedBio

What does AimedBio do?

AimedBio develops antibody-drug conjugate (ADC) therapeutics for solid tumors using its proprietary P-ADC™ platform, which leverages patient-derived cell and xenograft models for target discovery, antibody engineering, ADC optimization, and translational research. The company generates revenue by licensing ADC candidates (AMB302, ODS025) and entering co-development agreements (AMB303) with global pharmaceutical companies such as Biohaven, Boehringer Ingelheim, and SK Plasma, while also providing AVATASCAN® precision medicine screening services.

Is AimedBio a public or private company?

AimedBio is a public company. It is classified as public and is currently operating.

When was AimedBio founded?

AimedBio was founded in 2018. It employs 11 to 50 people.

Where is AimedBio based?

AimedBio is headquartered in Seoul, South Korea, in the Asia region.

How does AimedBio make money?

Three revenue lines are on record. Technology Licensing & Transfer is the primary driver. The others are co-development Revenue and government Grants.

Who are AimedBio's main competitors?

Direct peers on record are Pyxis Oncology, Tubulis, ProfoundBio, GeneQuantum Healthcare and Mersana Therapeutics. Emerging players are Bolt Biotherapeutics and Biohaven. LegoChem Biosciences is listed as a regional player. Broad incumbents are Innovent Biologics and Daiichi Sankyo.

Does AimedBio have an API?

No public API is recorded for AimedBio.

What industry is AimedBio in?

AimedBio's product category is Biopharmaceutical Oncology Drug Development. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageAimedBio and Boehringer Ingelheim initiate Phase I study of antibody-drug conjugate BI 4060107AimedBio and Boehringer Ingelheim initiated a Phase I study of BI 4060107, an antibody-drug conjugate, with the first patient dosed. The study evaluates doses in advanced solid tumors, and the milestone triggers a payment under their 2025 licensing agreement, with up to $991 million in total payments possible.FinanzNachrichten.deAimedBio and Boehringer Ingelheim initiate Phase I study of antibody-drug conjugate BI 4060107AimedBio and Boehringer Ingelheim initiated a Phase I study of antibody-drug conjugate BI 4060107, with the first patient dosed in advanced solid tumors. The milestone triggers a payment to AimedBio under their 2025 licensing agreement, with up to $991 million in total payments possible.TradingViewAimedBio Doses First Patient in Phase I ADC Trial; Milestone Payment TriggeredAimedBio dosed the first patient in a Phase I study of ADC BI 4060107 under its 2025 collaboration with Boehringer Ingelheim, triggering an undisclosed milestone payment. The company may receive up to $991M in milestones plus royalties. Next catalysts include initial Phase I safety and efficacy signals.TradingViewAimedBio and Boehringer Ingelheim initiate Phase I study of antibody-drug conjugate BI 4060107AimedBio and Boehringer Ingelheim initiated a Phase I study of antibody-drug conjugate BI 4060107, with the first patient dosed. The study evaluates doses in advanced solid tumors, and AimedBio is eligible for up to $991 million in milestone payments under their agreement.The future of tradingAimed Bio Expects Milestone Payment Under Boehringer Ingelheim Licensing DealAimed Bio expects a milestone payment under its ODS025 licensing agreement with Boehringer Ingelheim, signed Oct. 15, 2025. The payment represents at least 10% of 2025 consolidated revenue of approximately KRW 47.3 billion. Milestone confirmation arrived Oct. 26, 2026, with payment expected within 45 days of invoice receipt.Business Wire BlogAimedBio and Boehringer Ingelheim initiate Phase I study of antibody-drug conjugate BI 4060107AimedBio and Boehringer Ingelheim initiated a Phase I study of antibody-drug conjugate BI 4060107, with the first patient dosed in the first-in-human trial for advanced solid tumors. The milestone triggers a payment to AimedBio under their 2025 global licensing agreement, with up to $991 million in total payments available.StartuptodayMint Venture Partners proves the bio venture studio model... Portfolio companies listed on KOSDAQ.Mint Venture Partners announced that three portfolio companies—Organoid Science, Aimd Bio, and Meju—listed on KOSDAQ. Aimd Bio returned 23.1 times principal, Meju 9.1 times, and Organoid Science 1.47 times. The firm plans to raise two new funds and expand into AI healthcare.VenturesquareThree KOSDAQ companies and four direct startups... Mint Venture Partners, balancing investment and venture studio.Mint Venture Partners, a bio-healthcare venture studio, reports three KOSDAQ-listed companies from its first fund and four directly founded firms. The fund's portfolio includes 27 companies, and it has recovered its principal and benchmark return five years after formation. It plans to expand investment in AI healthcare and new drug development.스타트업엔(StartupN)Mint Venture Partners, three companies from the first fund are listed on KOSDAQ... The results of bio investments are becoming visible.Mint Venture Partners announced that three companies from its first blind fund—Organoid Science, AIMD Bio, and Meju—listed on KOSDAQ. AIMD Bio recovered 23.1 times its investment, Meju 9.1 times, and Organoid Science 1.47 times. The studio plans new funds and expansion into AI healthcare and precision medicine.PlatumMint Venture Partners recovers principal and benchmark returns 5 years after the formation of its first fund.Mint Venture Partners recovered principal and benchmark returns five years after its first fund, citing KOSDAQ listings of Organoid Science, Aimd Bio, and Meju. Return multiples were 23.1x, 9.1x, and 1.47x, respectively. The firm plans to expand into drug development, diagnostics, and AI healthcare.